Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 20Recruiting 17Terminated 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 28Carboplatin 18Cisplatin 15Nivolumab 13Pemetrexed 12Paclitaxel 11Specimen Handling 10Ipilimumab 10Gemcitabine 10venetoclax 8durvalumab 8atezolizumab 8Radiotherapy 8Radiosurgery 8Magnetic Resonance Spectroscopy 8Docetaxel 7Cyclophosphamide 7Biopsy 7fludarabine 6enzalutamide 6Bevacizumab 6tislelizumab 5tazemetostat 5X-Rays 5Trastuzumab 5Surveys and Questionnaires 5Practice Guidelines as Topic 5Interviews as Topic 5Injections 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × prednylidene × 90 days × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03360721 2026-03-16

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡